GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Capex-to-Operating-Cash-Flow

Vivesto AB (Vivesto AB) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Vivesto AB's Capital Expenditure for the three months ended in Dec. 2023 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $-1.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Vivesto AB Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Vivesto AB's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Capex-to-Operating-Cash-Flow Chart

Vivesto AB Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vivesto AB Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vivesto AB's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivesto AB's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Vivesto AB's Capex-to-Operating-Cash-Flow falls into.



Vivesto AB Capex-to-Operating-Cash-Flow Calculation

Vivesto AB's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.064) / -6.702
=N/A

Vivesto AB's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -1.003
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivesto AB  (OTCPK:OASMY) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Vivesto AB Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivesto AB (Vivesto AB) Business Description

Traded in Other Exchanges
Address
Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.

Vivesto AB (Vivesto AB) Headlines

From GuruFocus